OncoTartis OncoTartis OncoTartis OncoTartis
  • Home
  • Company
    • Team
  • Technology
    • TARTIS rationale
    • TARTIS disease targets
  • Pipeline
    • OT-82
  • News
  • Home
  • Company
    • Team
  • Technology
    • TARTIS rationale
    • TARTIS disease targets
  • Pipeline
    • OT-82
  • News

OncoTartis expanded its research facility by adding more than 2,300 square feet of the new custom-built laboratories equipped for a regular scientific bench work, as well as for testing cultured cancer cells response to discovered anti-cancer compounds.

Previous Next

OncoTartis expanded its research facility by adding more than 2,300 square feet of the new custom-built laboratories equipped for a regular scientific bench work, as well as for testing cultured cancer cells response to discovered anti-cancer compounds.

I78-tfw_yef-dg_rt 2014-04-01T18:05:01+00:00 April 1st, 2014|

Share This Story, Choose Your Platform!

FacebookTwitterLinkedinRedditTumblrGoogle+PinterestVkEmail

Recent News

  • OncoTartis, Inc. and Children’s Cancer Institute announced the publication of two research manuscripts in a leading onco-hematological journal Leukemia, both devoted to the OncoTartis’ clinical drug candidate OT-82. January 16, 2020
  • First patient has been recruited and received his first OT-82 treatment! July 17, 2019
  • Oncotartis, Inc has received a green light from FDA for its IND application. The Company will start engaging clinical sites immediately. It plans to use 5-10 clinical sites to conduct the trial. February 27, 2019
  • OncoTartis, Inc has hired a global, full-service contract research organization (CRO), Clinipace, to conduct a Phase 1/2a trial of its drug candidate OT-82 acting against hematological cancers. December 3, 2018
  • OncoTartis, Inc. has engaged Dr. Eric Rowinsky to serve an acting Medical Director. March 14, 2018

Contact Info

640 Ellicott St, Suite 480 Buffalo, NY 14203

Phone: 716.858.3055

Email: [email protected]

Web: www.oncotartis.com

Copyright 2016 OncoTartis, Inc. | Designed by Biotech Graphic Design